Development
Entrada Therapeutics' ENTR-601-44 meets primary safety goals in Duchenne muscular dystrophy trial
Entrada Therapeutics reported topline results from Cohort 1 of the Phase I/II ELEVATE-44-201 study evaluating ENTR-601-44 in ambulatory pediatric patients...
Ukko doses first participant in mRNA-LNP peanut allergy trial redirecting IgE to protective IgG response
Ukko, Inc., a Boston-based biotechnology company, has dosed the first participant in a Phase 1/2a clinical study evaluating UKK-0018 for peanut allergy,...
Pfizer pulls development of Trillium-acquired anti-CD47 inhibitor maplirpacept
Pfizer has terminated its Phase I/II study evaluating maplirpacept (PF-07901801), an anti-CD47 innate immune checkpoint inhibitor, in combination with...
Bayer's iodine 124 evuzamitide meets primary endpoints in Phase III cardiac amyloidosis imaging trial
Bayer has reported that iodine 124 evuzamitide met both primary endpoints in the Phase III REVEAL study, demonstrating sufficient sensitivity and...
Hoth Therapeutics' HT-001 shows efficacy for EGFR inhibitor-associated dermatologic toxicities in Phase IIa trial
Hoth Therapeutics reported interim Phase IIa results for HT-001 in cancer patients experiencing EGFR inhibitor-associated dermatologic toxicities, according...
Kali Therapeutics' CD19 × CD3 bispecific T-cell engager KT502 ready for Phase I in rheumatoid arthritis
Kali Therapeutics has initiated a first-in-human Phase I trial of KT502, a CD19 × CD3 bispecific T-cell engager administered subcutaneously, in adults with...
Fosun/Teva's anti-PD-1/IL-2 fusion protein FXB0871 to enter the clinic in China for PD-(L)1-resistant solid tumors
A first-in-human (FIH) clinical trial of FXB0871 (TEV-56278), an anti-PD-1/IL-2 antibody-cytokine fusion protein, has been registered in China, with HKEX-...
Cenna Biosciences' amyloid beta-targeting peptide 8M2D enters Phase I/b trial for early Alzheimer's disease
Cenna Biosciences is moving its synthetic peptide 8M2D — also referred to as Nubytide™ in prior company disclosures and as P8 in earlier academic literature...
Avalo Therapeutics' abdakibart meets primary endpoint in Phase II hidradenitis suppurativa trial
Avalo Therapeutics (Nasdaq: AVTX) reported that abdakibart, its anti-IL-1β monoclonal antibody, met the primary endpoint in the Phase II LOTUS trial in...
Cytokinetics' aficamten meets endpoints in Phase III non-obstructive cardiomyopathy trial, nudging ahead of BMS
Cytokinetics (Nasdaq: CYTK) reported that aficamten met both dual primary endpoints in the Phase III ACACIA-HCM trial in symptomatic non-obstructive...
Johnson & Johnson's guselkumab demonstrates efficacy in Phase III perianal fistulizing Crohn's disease trial
Johnson & Johnson (NYSE: JNJ) reported that guselkumab (Tremfya) met the primary endpoint of combined fistula remission in the Phase III FUZION study in...
BrightGene posts 19.3% weight reduction in Phase III obesity trial for GLP-1/GIP injection
BrightGene Bio-Medical Technology Co., Ltd. (688166.SH) reported that BGM0504, its GLP-1/GIP dual receptor agonist, reduced body weight by a mean of 19.3%...
Mirum's volixibat meets primary endpoint in Phase IIb primary sclerosing cholangitis trial
Mirum Pharmaceuticals (Nasdaq: MIRM) reported that volixibat met the primary endpoint in the Phase IIb VISTAS study, producing a statistically significant...
Johnson & Johnson's JNJ-4804 doubles clinical remission in Phase IIb refractory Crohn's disease trial
Johnson & Johnson (NYSE: JNJ) reported Phase IIb data showing that JNJ-4804, its investigational co-antibody combining guselkumab and golimumab, produced...
Viridian's elegrobart meets primary endpoint in Phase III chronic thyroid eye disease trial
Viridian Therapeutics (Nasdaq: VRDN) reported that elegrobart met its primary endpoint in the Phase III REVEAL-2 trial in chronic thyroid eye disease, with...
The AllSci Brief
Systematic R&D and deal news. Daily.